ACTA MEDICA MEDITERRANEA, cilt.30, sa.2, ss.465-471, 2014 (SCI-Expanded)
Background: Several clinical studies have shown the effect of mefformine on survival in pancreatic cancer. We aimed to evaluate whether the use of mefformin in diabetic pancreatic cancer patients provides a survival advantage or not.